Literature DB >> 2580935

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.

A Doyle, W J Martin, K Funa, A Gazdar, D Carney, S E Martin, I Linnoila, F Cuttitta, J Mulshine, P Bunn.   

Abstract

We have found markedly deficient expression of the class I major histocompatibility antigens HLA-A,B,C and beta 2m on human small-cell lung cancer (SCLC) lines and fresh tumor samples. The deficit of HLA-A,B,C and beta 2-microglobulin (beta 2m) antigen expression was demonstrated with both radiobinding assays and indirect immunofluorescence assays. Immunoprecipitation of metabolically labeled cells with antibodies to class I antigens showed most SCLC lines to have synthesized almost no beta 2m and HLA-A,B,C proteins. Northern blot analysis, using human HLA-A,B, and beta 2m cDNA probes, showed that almost all SCLC lines tested had markedly decreased amounts of HLA and beta 2m mRNA, but both gene products could be induced with interferon treatment of SCLC lines. We conclude that human SCLC, in contrast to other lung cancer types, is characterized by greatly reduced transcription of HLA-A,B,C and beta 2m genes, which suggests the existence of a mechanism for evading the host immune response to the tumor and of an E1a-like product in this type of tumor cell.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580935      PMCID: PMC2187608          DOI: 10.1084/jem.161.5.1135

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.

Authors:  M Fellous; U Nir; D Wallach; G Merlin; M Rubinstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

3.  Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin.

Authors:  S V Suggs; R B Wallace; T Hirose; E H Kawashima; K Itakura
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

4.  Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines.

Authors:  T Y Basham; M F Bourgeade; A A Creasey; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

Review 5.  T/t locus, its role in embryogenesis and its relation to classical histocompatibility systems.

Authors:  D Bennett
Journal:  Prog Allergy       Date:  1981

6.  A crucial role of the H-2 D locus in the regulation of both the D- and the K-associated cytotoxic T lymphocyte response against Moloney leukemia virus, demonstrated with two Db mutants.

Authors:  M J Stukart; A Vos; J Boes; R W Melvold; D W Bailey; C J Melief
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

7.  The free and the beta 2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28.

Authors:  V Quaranta; L E Walker; G Ruberto; M A Pellegrino; S Ferrone
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

8.  A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC).

Authors:  J Whang-Peng; P A Bunn; C S Kao-Shan; E C Lee; D N Carney; A Gazdar; J D Minna
Journal:  Cancer Genet Cytogenet       Date:  1982-06

9.  Control of expression of histocompatibility antigens (H-2) and beta 2-microglobulin in F9 teratocarcinoma stem cells.

Authors:  C M Croce; A Linnenbach; K Huebner; J R Parnes; D H Margulies; E Appella; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

10.  Monoclonal antibodies that demonstrate specificity for several types of human lung cancer.

Authors:  F Cuttitta; S Rosen; A F Gazdar; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

View more
  102 in total

1.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

Review 2.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

3.  Inhibition of HLA class I antigen and mRNA expression induced by Rous sarcoma virus in transformed human fibroblasts.

Authors:  J Gogusev; B Teutsch; M T Morin; F Mongiat; F Haguenau; G Suskind; G F Rabotti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

4.  Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant.

Authors:  S P Cole; B M Campigotto; J G Johnson; B E Elliott
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Developmental and tissue-specific expression of the Q5k gene.

Authors:  S Schwemmle; D Bevec; G Brem; M B Urban; P A Baeuerle; E H Weiss
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 6.  Class I genes and molecules: an update.

Authors:  A M Lew; E P Lillehoj; E P Cowan; W L Maloy; M R van Schravendijk; J E Coligan
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

7.  Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.

Authors:  Denise L Crossland; Warren L Denning; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Kate S Gold; Bonnie S Glisson; Laurence J Cooper; John V Heymach
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

Review 8.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

9.  Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene.

Authors:  M E Sunday; K J Isselbacher; S Gattoni-Celli; C G Willett
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

10.  The role of major histocompatibility complex expression on head and neck cancer cells in the induction of autologous cytotoxic T lymphocytes.

Authors:  K Chikamatsu; M Eura; H Matsuoka; H Murakami; T Fukiage; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.